<p>Curative Biotechnology Inc. announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for its patent application entitled “Druggable Target to Treat Retinal Degeneration” (Application No. 3,151,011). The patent includes 22 allowed claims, covering topical ocular delivery approaches relevant to metformin-based formulations. The invention was developed under a license from the National Eye Institute and focuses on a novel pharmacological target for retinal degenerative diseases. The company also plans to expand development into select canine retinal degenerative indications, including Progressive Retinal Atrophy and Progressive Rod and Cone Disease. The patent is expected to formally issue in the coming months. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curative Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9631486) on January 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

CUBT

Curative Biotechnology Receives Canadian Patent Allowance for Metformin-Based Eye Drop Technology to Treat Retinal Degeneration